EAU-ESMO晚期及变异型膀胱癌管理共识:国际多利益相关方协作
该共识由EAU与ESMO联合组织113名专家通过Delphi调查和共识会议制定,针对晚期及变异型膀胱癌管理中的争议话题。116条声明中33条(28%)达level 1共识,49条(42%)达level 1或2共识;共识会议27条中22条(81%)达成共识,最终71条声明获共识。
要点
- 116条声明经113名专家Delphi调查,49条达level 1或2共识
- 共识会议27条中22条(81%)达成共识
- 共识覆盖变异组织学、生物标志物、膀胱保留、放疗、寡转移及免疫治疗
核心结论
- 共识声明为晚期及变异型膀胱癌争议话题提供指导,直至更高质量证据出现。
研究设计与样本
- 指导委员会编制声明,113名专家参与在线Delphi调查,45名专家在共识会议前修订优先声明并投票。
- 共识定义为≥70%同意且≤15%不同意(或反之),限定相关利益方分析达level 2共识。
主要发现
- Delphi调查纳入116条声明,33条(28%)达level 1共识,49条(42%)达level 1或2共识。
- 共识会议27条声明中22条(81%)达成共识。
- 最终71条声明获共识。
关键数值与推荐
- 共识阈值:≥70%同意且≤15%不同意,或反之。
- 声明按同意程度1-3(不同意)、4-6(模棱两可)、7-9(同意)排序。
临床怎么用
- 共识声明可用于指导变异组织学、预后生物标志物、膀胱保留策略、现代放疗、寡转移疾病及检查点抑制剂治疗等临床决策。
局限性
- 部分领域证据有限或存在矛盾,共识声明基于专家意见而非高质量证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. PATIENT SUMMARY: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.
引用
- Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol. 2019. PMID: 31753752. doi:10.1016/j.eururo.2019.09.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。